Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 8910 results

  1. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]

    Awaiting development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]

    Awaiting development Reference number: GID-TA11830 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bepirovirsen for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    In development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]

    In development Reference number: GID-TA11699 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date: TBC

    NICE guideline
    In development

  12. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Implanting a baroreceptor stimulation device for resistant hypertension

    In development Reference number: GID-IP1180 Expected publication date: TBC

    Interventional procedures guidance
    In development

  14. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development